Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | TLR4 | O00206 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL879216 | 0.87 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2772711 | 0.85 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1287501 | 0.84 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7930158 | 0.84 | LMNA (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL198840 | 0.83 | MAPK1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL15083809 | 0.83 | CA12 (0.46) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9446767 | 0.83 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18940424 | 0.83 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL22912516 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18940470 | 0.83 | CA12 (0.53) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0394476-B1 | NOVEL 1,3,4-THIADIAZOLE DERIVATIVES AND ANTIULCER AGENTS CONTAINING SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1993-07-28 | — | — | EP | claimed |
| EP-0394476-A1 | NOVEL 1,3,4-THIADIAZOLE DERIVATIVES AND ANTIULCER AGENTS CONTAINING SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1990-10-31 | — | — | EP | claimed |
| JP-2096577-A | — | — | None | — | — | JP | disclosed |
| US-11814371-B2 | Heterocyclic compound | MEDSHINE DISCOVERY INC. (CN) | 2023-11-14 | — | — | US | disclosed |
| US-20230167098-A1 | HETEROCYCLIC COMPOUND | MEDSHINE DISCOVERY INC. (CN) | 2023-06-01 | — | — | US | disclosed |
| EP-4116299-A1 | HETEROCYCLIC COMPOUND | Medshine Discovery Inc. (CN) | 2023-01-11 | — | — | EP | disclosed |
| CN-103420977-B | There is the acetylene-derivative of anti-tumor activity | 上海医药集团股份有限公司 | 2016-06-22 | — | — | CN | disclosed |
| EP-0394476-B1 | NOVEL 1,3,4-THIADIAZOLE DERIVATIVES AND ANTIULCER AGENTS CONTAINING SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1993-07-28 | — | — | EP | disclosed |
| US-5106859-A | CERTAIN 1,3,4-THIADIAZOLE DERIVATIVES AND ANTI-ULCER AGENT COMPRISING SAID DERIVATIVES AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1992-04-21 | — | — | US | disclosed |
| EP-0394476-A1 | NOVEL 1,3,4-THIADIAZOLE DERIVATIVES AND ANTIULCER AGENTS CONTAINING SAME AS ACTIVE INGREDIENT | TSUMURA & CO. (JP) | 1990-10-31 | — | — | EP | disclosed |
| JP-H0296577-A | NOVEL 1,3,4-THIADIAZOLE DERIVATIVE AND ANTI-ULCER AGENT CONTAINING THE SAME DERIVATIVE AS ACTIVE INGREDIENT | TSUMURA & CO | 1990-04-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167098-A1 | HETEROCYCLIC COMPOUND | CYP11B2, CYP4F11, CYP11B1 | CA12 2305/4885CA1 3792/4885CA2 4185/4885 |
| US-11814371-B2 | Heterocyclic compound | CYP11B2, CYP4F11, CYP11B1 | CA12 2305/4885CA1 3792/4885CA2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.